Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area

Craig Leonardi, MD; Linda Stein Gold, MD; Edward Lain, MD, MBA; Andrea Neumann, MD; Abby Jacobson, MS, PA-C

1Department of Dermatology, St. Louis Medical School, St. Louis, MO; 2Henry Ford Hospital, Detroit, MI; 3Austen Institute for Clinical Research, Austin, TX; 4Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York, NY; 5Ortho Dermatologics*, Bridgewater, NJ

SYNOPSIS

Medical writing support was provided by Prescott Medical Communications Group (Chicago, IL) with financial support from Ortho Dermatologics; Ortho Dermatologics is a division of Bausch Health US, LLC

The incidence of treatment-emergent adverse events (TEAEs) with HP/TAZ was similar in the 3-5% BSA subgroup and the overall population.

OBJECTIVE

The primary objective of these two studies was to evaluate the efficacy, safety, and tolerability of HP/TAZ lotion for the treatment of plaque psoriasis in patients with 3-5% BSA involvement.

METHODS

In these studies, CeraVe® hydrating cleanser and CeraVe® hydrating moisturizer were applied twice daily to the entire body, including the target lesion. Patients maintained their existing skin care regimens, except during the treatment period.

RESULTS

Demographics and Baseline Characteristics

A total of 418 participants were included in the overall study population (baseline BSA of 3-12%, mean 5.3%); of these participants, 232 (55.5%) had baseline BSA of 3-5% (mean 3.9%).

Participant demographics (age, sex, race) were similar between groups, though a higher proportion of participants with 3-5% BSA had a baseline Investigator’s Global Assessment (IGA) score of 3 (moderate, 91.4%) versus the overall population (25.4%).

Efficacy of HP/TAZ Lotion

A once-daily, fixed combination HP 0.01%/TAZ 0.045% lotion (Duobrii, Ortho Dermatologics) was developed to address these unmet needs in the topical treatment of psoriasis.

In these studies, HP/TAZ demonstrated rapid efficacy versus vehicle and clinically meaningful improvement in quality of life (QoL) in patients with mild-to-moderate disease.

In a separate analysis by baseline IGA, HP/TAZ-treated participants with moderate psoriasis (IGA 3) experienced fewer irritation-related AEs than those with severe psoriasis (IGA 4; data not shown).

Conclusions

In two pooled phase 3 studies, HP/TAZ lotion demonstrated rapid efficacy versus vehicle and clinically meaningful improvement in QoL among participants with lower than 3-5% affected BSA at baseline, with improvements maintained 4 weeks posttreatment.

HP/TAZ lotion may be an effective and well-tolerated option for the treatment of “milder” psoriasis in patients with lower BSA involvement.

REFERENCES


AUTHOR DISCLOSURES


Mailing address: Craig Leonardi, MD, Department of Dermatology, St. Louis Medical School, Washington University School of Medicine, 1 Brookline Blvd., St. Louis, MO 63110, USA.